Target intelligence / Profile preview

Tumor necrosis factor ligand superfamily member 18 (TNFSF18) (GITRL)

Target
GITRL
Molecular classification
Tumor necrosis factor (TNF) ligand superfamily, Cytokine, Type II transmembrane protein
01

Overview

Tumor necrosis factor ligand superfamily member 18 (TNFSF18), commonly known as GITR ligand (GITRL), is a type II transmembrane protein that serves as the primary ligand for the glucocorticoid-induced TNFR-related protein (GITR). It is predominantly expressed on antigen-presenting cells, such as dendritic cells, macrophages, and B cells, as well as on endothelial cells. The interaction between GITRL and its receptor, GITR, provides a critical co-stimulatory signal that enhances the activation, proliferation, and survival of effector T cells while simultaneously abrogating the suppressive function of regulatory T cells (Tregs). This dual mechanism makes the GITR-GITRL pathway a significant target in immuno-oncology, where agonists are used to stimulate anti-tumor immunity. Beyond its role in cancer, GITRL is involved in the pathogenesis of autoimmune and inflammatory diseases, where its overactivity can lead to tissue damage, making it a target for antagonistic therapies. Additionally, GITRL can engage in reverse signaling, influencing the function of the ligand-bearing cells themselves, such as promoting a pro-inflammatory phenotype in macrophages.

Other names
GITRLTNFSF18AITRLTL6hGITRLGlucocorticoid-induced TNF-related ligandActivation-inducible TNF-related ligand
02

Mechanism of action

Agonism (mimicking natural ligand to activate GITR signaling) and Antagonism (blocking GITRL-GITR interaction)

03

Biological functions

T-cell activationT-cell proliferationCytokine productionRegulatory T-cell (Treg) suppressionImmune response modulationLeukocyte adhesion to endothelial cellsMacrophage polarizationReverse signaling
04

Disease associations

CancerInflammationAutoimmune diseaseAtherosclerosisInfection
05

Safety considerations

Cytokine release syndromeAutoimmunity (breaking self-tolerance)Immunosuppression (with antagonists)Infusion-related reactionsHeadacheDecreased appetite
06

Interacting drugs

MEDI1873

1 more in the full profile.

07

Biomarkers

GITRL expression on antigen-presenting cellsGITRL mRNA levelsGITR expression on T cellsKi67+ CD4+ T cellsInterferon-gamma (IFN-gamma) levels

Beyond the preview

Go deeper on Tumor necrosis factor ligand superfamily member 18 (TNFSF18) (GITRL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor necrosis factor ligand superfamily member 18 (TNFSF18) (GITRL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call